A Phase 2 interventional study of Standard treatment+mirabegron and Standard treatment in Intracerebral Haemorrhage, sponsored by Tianjin Medical University General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Tianjin Medical University General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.
Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 71st largest by planned enrollment of the 77 interventional ones that give a count, is one of 13 that started in 2024, is one of 13 in phase 2, reaches primary completion later than 32 of the 61 other live ones, and was the 54th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Jiangsu Province (Suqian) Hospital · Sites in China
Ages 65+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Yanyan Gong · Sites in China
Ages 18–85
Beijing Tiantan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 14 · Phase 4 4
First in 2005; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 180 across the 77 interventional studies, 664 across the 46 observational. Of the 31 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 123 have an industry lead sponsor. The 10 most frequent:
Tianjin Medical University General Hospital is the lead sponsor of 75 studies on the registry; 31 are open to participants now.
Tianjin Medical University General Hospital has 2 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
14 of the studies in Cerebral Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868511Phase 3Beijing Tiantan HospitalNeuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage | 2027-03-01 |
| NCT06688162Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage--Small Hemorrhage Evacuation (MIRACLE-S) | 2026-11-30 |
| NCT06688201Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage-- Large Hemorrhage Evacuation (MIRACLE-L) | 2026-11-30 |
| NCT03571763General Hospital of Shenyang Military RegionThe Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients | 2026-12-30 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 123 studies in Cerebral Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes without effective pharmacological treatment. Inflammation following ICH contributes to barrier disruption and peri-hematoma edema, leading to deterioration of neurological function. Preclinical evidence suggests that bone marrow hematopoietic stem and progenitor cells (HSPCs) are swiftly activated after ICH. Thereafter, these HSPCs produce an increased output of anti-inflammatory monocytes as an endogenous protective mechanism. Stimulation of β3 adrenergic receptor using selective agonists promotes the production of anti-inflammatory monocytes in bone marrow, and thereby reduces neuroinflammation, brain edema and neurological deficits. This study is to assess the safety and efficacy of a β3 adrenergic receptor agonist Mirabegron as a potential treatment option in ICH patients.
This study is to evaluate the efficacy and safety of mirabegron in patients with intracerebral hemorrhage based on standard therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
Drug: Standard treatment+mirabegron
Patients will receive usual care
Other: Standard treatment
Drug page: MirabegronStudies of MirabegronMirabegron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
Standard treatment
Changes in absolute perihematomal edema volume measured by computed tomography (CT)
Repeated CT images will be obtained at 24-48 hours after diagnosis and on days 7 and 14 with CT at 24-48 hours after diagnosis as the baseline for analysis.
Time frame: 7 and 14 days
Changes in absolute hematoma volume measured by CT after ICH
Repeated CT images will be obtained at 24-48 hours after diagnosis and on days 7 and 14 with CT at 24-48 hours after diagnosis as the baseline for analysis.
Time frame: 7 and 14 days
Changes in NIHSS scores
The assessment will be based on the National Institutes of Health Stroke Scale (NIHSS) with a score range of 0 (asymptomatic) to 42 (death).
Time frame: 7 and 14 days
The rate of functional independence at 90 days
Number of participants with functional independence. Modified Rankin scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes neurological disability. Functional Independence: 0 - no symptoms at all 1 - no significant disability despite symptoms; able to carry out all usual duties and activities 2- slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
Time frame: 90 days
Proportion of adverse drug reactions
Adverse events related to mirabegron will be recorded.
Time frame: 14 days
All cause mortality
Death induced by any cause
Time frame: 90 days
Changes of immune cells in peripheral blood
The counts of monocytes subsets and other immune cells in peripheral blood were compared.
Time frame: 14 days
Started Jan 2024 (actual). Primary completion is estimated for Aug 2027, 42 months after the start.
Of 24 phase 2 interventional studies under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 42 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Aug 2026 → Aug 2027 and completion Nov 2026 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirabegron
Tianjin Medical University General Hospital